Implementing the use of long-acting (LA) antiretrovirals (ARVs) into routine clinical practice requires a complex, interdisciplinary approach. These recommendations will assist clinicians in optimizing use of the five LA ARVs that are currently available in a limited number of countries worldwide for the prevention or treatment of HIV-1.

The consensus recommendations for the use of LA ARV medications in the treatment and prevention of HIV-1 were developed by a multidisciplinary panel of experts in infectious diseases, led by ACCP member Elizabeth Sherman. Five additional ACCP members contributed to the recommendations: Melissa E. Badowski, Humberto R. Jimenez, Nancy N. Nguyen, Neha Sheth Pandit, and Kimberly K. Scarsi. Five organizations have reviewed and endorsed the recommendations: the American College of Clinical Pharmacy, American Academy of HIV Medicine, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists.

The consensus recommendations provide guidance on the clinical use of LA ARV agents for diverse patient groups in different practice settings. The Consensus Recommendations and Executive Summary are published open access in the July 2024 issue of Pharmacotherapy, an official journal of ACCP.